Clinical Trial

Study to Assess the Adverse Events, Tolerability, and How Oral Doses of ABBV-932 Moves Through the Body in Healthy Adult Chinese Participants

Completed Phase 1
View on ClinicalTrials.gov →
Summary
This study will assess the adverse events, tolerability, and how oral doses of ABBV-932 moves through the body in healthy adult Chinese participants.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2025-06-09; most recent amendment 2025-12-26.
Status change: Recruiting → Completed 2025-12-26
Status change: Not Yet Recruiting → Recruiting 2025-08-26
Trial Details
NCT Number NCT07024797
Lead Sponsor AbbVie
Conditions Healthy Volunteer
Enrollment 20 participants
Start Date 2025-08-21
Primary Completion 2025-12-08 (estimated)
Study Completion 2025-12-08 (estimated)
Updated on ClinicalTrials.gov 2025-12-31